Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery
Sponsor: Beijing Tiantan Hospital
Summary
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.
Official title: Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Minimally Invasive Endoscopic Surgery
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
588
Start Date
2025-06-17
Completion Date
2026-12-31
Last Updated
2025-11-18
Healthy Volunteers
No
Conditions
Interventions
Dexamethasone palmitate
Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
Dexamethasone
Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
Locations (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China